|
25 Feb 2021 |
AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
|
|
25 Feb 2021 |
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
|
|
25 Feb 2021 |
Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study
|
|
24 Feb 2021 |
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
|
|
24 Feb 2021 |
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
|
|
23 Feb 2021 |
INOVIO announces first subject dosed in Phase 1B clinical trial for its DNA vaccine against Lassa fever, INO-4500, in West Africa
|
|
22 Feb 2021 |
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
|
|
22 Feb 2021 |
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
|
|
22 Feb 2021 |
Amyris Announces Positive Pre-Clinical Results For COVID-19 RNA Vaccine Platform With Advantaged Manufacturing, Storage And Distribution Characteristics
|
|
22 Feb 2021 |
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
|
|
20 Feb 2021 |
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
|
|
20 Feb 2021 |
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
|
|
19 Feb 2021 |
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
|
|
19 Feb 2021 |
Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women
|
|
18 Feb 2021 |
Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
|
|
17 Feb 2021 |
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
|
|
17 Feb 2021 |
Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
|
|
16 Feb 2021 |
AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
|
|
12 Feb 2021 |
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
|
|
12 Feb 2021 |
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
|
|
10 Feb 2021 |
AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
|
|
08 Feb 2021 |
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
|
|
08 Feb 2021 |
COVAXX’s COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants During Phase 1 Clinical Trial
|
|
06 Feb 2021 |
Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell Responses >25 Fold Higher Than Benchmark Vaccines
|
|
06 Feb 2021 |
Sinovac Announces Phase III Results of Its COVID-19 Vaccine
|
